SCHEMBL4293565

SCHEMBL4293565

CCOC(=O)C1(C(=O)OCC)CC[C@H](N)C1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 1/20 0.35
ALOX15 P16050 1/20 0.34
GAA P10253 1/20 0.34
PPM1B O75688 1/20 0.33
PTPN1 P18031 1/20 0.33
POLB P06746 1/20 0.33
PPP1CC P36873 1/20 0.33
F10 P00742 1/20 0.33
MAPK1 P28482 1/20 0.33
OPRM1 P35372 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 2/20 0.32
OPRD1 P41143 2/20 0.32
OPRK1 P41145 2/20 0.32
SLC22A1 O15245 1/20 0.32
SLC6A4 P31645 1/20 0.32
ADRA1A P35348 1/20 0.32
KCNH2 Q12809 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5814077 1.00 SMYD3 (0.35) SMYD3ALOX15GAAPPM1BPTPN1
SCHEMBL30829113 1.00 SMYD3 (0.35) SMYD3ALOX15GAAPPM1BPTPN1
Hydrochloric Acid SCHEMBL4295691 0.98 SMYD3 (0.34) SMYD3ALOX15GAAPPM1BPTPN1
SCHEMBL7409982 0.89 SMYD3 (0.40) SMYD3ALOX15GAAPPM1BPTPN1
SCHEMBL34461866 0.85 ALOX15 (0.39) SMYD3ALOX15GAAPPM1BPTPN1
SCHEMBL17708939 0.81 BRD4 (0.35) SMYD3ALOX15GAAPPM1BPTPN1
SCHEMBL4287007 0.80 F10 (0.36) POLBF10MAPK1OPRM1SMN1; SMN2
SCHEMBL28017152 0.80 ALOX15 (0.35) SMYD3ALOX15GAAPPM1BPTPN1
SCHEMBL17017270 0.79 POLB (0.33) GAAPOLBF10MAPK1OPRM1
SCHEMBL24313214 0.76 SMYD3 (0.39) SMYD3ALOX15GAAPPM1BPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024206628-A1 MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN NALO THERAPEUTICS (US) 2024-10-03 WO disclosed
US-20090264469-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES BIO-PROJET (FR) 2009-10-22 US disclosed
US-20090264469-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES BIO-PROJET (FR) 2009-10-22 US disclosed
US-20090264469-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES BIO-PROJET (FR) 2009-10-22 US disclosed
WO-2006043149-A9 NOVEL DICARBOXYLIC ACID DERIVATIVES BIOPROJET SOC CIV (FR) 2006-08-10 WO disclosed
WO-2006043149-A2 NOVEL DICARBOXYLIC ACID DERIVATIVES BIOPROJET (FR) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264469-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES S1PR2, S1PR1, S1PR5 SMYD3 3314/4885ALOX15 1046/4885GAA 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.